RECORD // Company

Adaptive Biotechnologies Corp

Formerly: Adaptive TCR Corp

Built 2026-11-21T07:16:24Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (12)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

7 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001193125-26-447411

ItemValuePeriodFormFiledAccessionReport
Revenue$83,902,0003 months ended 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error
Net income (loss)$2,876,0003 months ended 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error
Interest expense$503,0003 months ended 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error
Cash and cash equivalents$75,615,000at 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error
Contract liabilities (total)$60,403,000at 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error
Contract liabilities, current$59,995,000at 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error
Contract liabilities, noncurrent$408,000at 2026-09-3010-Q2026-11-040001193125-26-4474112026-11-21 07:16 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001478320
Ticker
ADPT
EIN
270907024
UEI
DMW5BNQ331K9
CUSIP
00650F109
Record ID
sx:sec:0001478320

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

36 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-13SEC EDGAR company profile2026-11-21 07:16 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-13SEC EDGAR company profile2026-11-21 07:16 UTCReport an error
State of incorporationWA2026-11-13SEC EDGAR company profile2026-11-21 07:16 UTCReport an error
Fiscal year end (MMDD)12312026-11-13SEC EDGAR company profile2026-11-21 07:16 UTCReport an error
Business address1165 EASTLAKE AVE E, SEATTLE, WA, 981092026-11-13SEC EDGAR company profile2026-11-21 07:16 UTCReport an error
ExchangesNasdaq2026-11-13SEC EDGAR company profile2026-11-21 07:16 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$276,976,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 07:16 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-59,499,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 07:16 UTCReport an error
Total assets (at 2025-12-31)$512,736,0002025-12-3110-K, XBRL Assets2026-11-21 07:16 UTCReport an error
Stockholders' equity (at 2025-12-31)$218,793,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 07:16 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$70,495,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 07:16 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-45,986,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 07:16 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$2,959,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 07:16 UTCReport an error
Long-term debt (at 2025-12-31)$126,566,0002025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-21 07:16 UTCReport an error
Operating lease liabilities (at 2025-12-31)$79,148,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 07:16 UTCReport an error
Form D total offering amount (D filed 2015-05-11)$195,099,9542015-05-11D2026-11-21 07:16 UTCReport an error
Form D total amount sold (D filed 2015-05-11)$195,099,9542015-05-11D2026-11-21 07:16 UTCReport an error
Form D industry groupBiotechnology2015-05-11D2026-11-21 07:16 UTCReport an error
Form D revenue rangeDecline to Disclose2015-05-11D2026-11-21 07:16 UTCReport an error
Form D date of first sale2015-05-052015-05-11D2026-11-21 07:16 UTCReport an error
8-K Item 2.02 (filed 2026-11-04)Results of Operations and Financial Condition. On November 4, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as…2026-11-04SEC EDGAR 8-K 0001193125-26-447290 (text as filed, excerpt)2026-11-21 07:16 UTCReport an error
8-K Item 2.02 (filed 2026-07-29)Results of Operations and Financial Condition. On July 29, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be…2026-07-29SEC EDGAR 8-K 0001193125-26-323753 (text as filed, excerpt)2026-11-21 07:16 UTCReport an error
8-K Item 5.02 (filed 2026-07-29)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 24, 2026, the Company’s Chief Scientific Officer and Co-founder, Dr. Harlan Robins, decided to transition into a strategic consultant role with the Company. The Company expects to enter into a consulting agreement with Dr. Robins on its standard form pursuant to which he would support research and development efforts for the minimal residual disease business and the separation of the immune medicine business. There are no disagreements or performance matters related to Dr. Robins's decision.2026-07-29SEC EDGAR 8-K 0001193125-26-323753 (text as filed, excerpt)2026-11-21 07:16 UTCReport an error
Plan (pension, plan no. 001)ADAPTIVE BIOTECHNOLOGIES CORPORATION 401(K) PLAN: 930 participants, assets $85,630,8502025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 07:16 UTCReport an error
Largest institutional holder #1 (13F as filed): VIKING GLOBAL INVESTORS LP$643,365,0372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$324,734,9622026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$137,356,9412026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #4 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP$126,798,8022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$117,465,1552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #6 (13F as filed): D. E. Shaw & Co., Inc.$99,224,6752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #7 (13F as filed): WESTFIELD CAPITAL MANAGEMENT CO LP$91,540,9852026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$78,131,2032026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #9 (13F as filed): STATE STREET CORP$74,181,6362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Largest institutional holder #10 (13F as filed): Invesco Ltd.$66,366,5352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:16 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$250,3552026-09-30USAspending recipient profile2026-11-21 07:16 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)202026-09-30USAspending recipient profile2026-11-21 07:16 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.